A Phase 2 interventional study of Bremelanotide in Sexual Arousal Disorder, sponsored by Palatin Technologies, Inc. Completed at 20 sites in United States. Open to female participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-02-23.
Sponsored by Palatin Technologies, Inc · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is one of 7 that started in 2006, is one of 13 in phase 2, and was the 14th registered.
138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.
Browse Sexual Dysfunctions, Psychological studies →3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:
Urological Research Network, LLC · Sites in United States
Ages 50–80 · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
San Diego Sexual Medicine · Sites in United States
Ages 21–75 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 21 Years to 70 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 27 · Phase 4 2
First in 2002; this study’s year is marked. 7 started in 2006.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 196 across the 59 interventional studies, 18 across the 1 observational. Of the 53 that completed or were terminated, 20 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 62 have an industry lead sponsor. The 10 most frequent:
Palatin Technologies, Inc is the lead sponsor of 11 studies on the registry; none are open to participants now.
Palatin Technologies, Inc has 4 studies filed under Sexual Dysfunctions, Psychological — fewer than ten, so there is no comparison to draw.
2 of the studies in Sexual Dysfunctions, Psychological with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05777031University of MiamiSafety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease | 2027-01-15 |
| NCT06458049Dana-Farber Cancer InstituteSexual Health and Rehabilitation Online (SHAREonline) | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Inclusion Criteria:
The record gives a start of Feb 2006, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bremelanotide
Sexual Dysfunctions, Psychological →
Palatin Technologies, Inc